--Blackstone Inc. and Carlyle Group Inc. are in discussions to team up to bid for Novartis AG's generic-drugs unit Sandoz, which could be valued at $25 billion, Bloomberg reports, citing unnamed sources.

--Advent International Corp., Hellman & Friedman LLC, KKR & Co. and EQT AB are separately considering bids, Bloomberg says.

--Some of the private equity companies could join up due to Sandoz's size, according to Bloomberg.

--Novartis hasn't made a final decision on whether to spin off or sell the unit, Bloomberg adds.

 

Full story: https://bloom.bg/3gfuZ8N

 

Write to Ed Frankl at edward.frankl@dowjones.com

 

(END) Dow Jones Newswires

February 01, 2022 11:20 ET (16:20 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024 Click aqui para mais gráficos Novartis.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024 Click aqui para mais gráficos Novartis.